<DOC>
	<DOCNO>NCT01438632</DOCNO>
	<brief_summary>A previous study show absorption glucose-lowering action rapid-acting insulin analogue occur twice fast analogue administer jet injection technology rather conventional insulin pen healthy non-diabetic subject . This study investigate rapid-acting insulin analogue aspart ( Novorapid® ) inject jet-injection conventional insulin pen prior standardised meal patient diabetes show difference pharmacokinetic pharmacodynamic profile .</brief_summary>
	<brief_title>Pharmacology Insulin Injected With Jet-injection Diabetes</brief_title>
	<detailed_description>A previous study show absorption glucose-lowering action rapid-acting insulin analogue occur twice fast analogue administer jet injection technology rather conventional insulin pen healthy non-diabetic subject . This study investigate rapid-acting insulin analogue aspart ( Novorapid® ) inject jet-injection conventional insulin pen prior standardised meal patient diabetes ( type 1 type 2 ) show difference pharmacokinetic pharmacodynamic profile.The pharmacokinetic pharmacodynamic profile insulin aspart derive time-action profile insulin glucose , respectively , response insulin inject directly prior standardise meal . All patient investigate twice , one occasion jet-injector device use inject individualise dose insulin conventional insulin pen inject placebo solution , occasion insulin inject conventional pen placebo jet-injector . The order occasion randomise blinded investigator participate patient . The primary endpoint hyperglycaemic burden reflect area baseline-subtracted plasma glucose concentration time-curve time 0 2 h insulin injection meal ingestion ( BG-AUC0-2h ) . Secondary study endpoint area baseline-subtracted plasma glucose concentration time-curve time 0 6 h ( BG-AUC0-6h ) , maximal glucose excursion ( BGmax ) , time maximal glucose excursion ( T-BGmax ) , time plasma glucose return baseline ( T-BGBL ) , maximal insulin concentration ( C-INSmax ) , time maximal insulin concentration ( T-INSmax ) , area insulin concentration curve ( INSAUC ) time 50 % insulin absorption ( T-INSAUC50 % ) insulin injection meal ingestion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<criteria>Bodymass index 1832 kg/m2 Stable glycaemic control HbA1c 6.09.0 % Duration diabetes &gt; 1 year Insulin use least daily subcutaneous pump Blood pressure &lt; 160/90 mmHg Inability provide inform consent Requirement &lt; 8 unit rapidacting insulin ( analogue ) meal Chronic use sulphonylurea derivative , GLP1 base treatment , acarbose thiazolidinediones Treatment prednisolone , nonsteroidal antiinflammatory drug ( NSAIDs ) , immunosuppressive agent , cytostatic drug , hormone therapy except insulin , thyroid supplementation oral anticonceptives Known allergy aspart insulin Symptomatic diabetic neuropathy History major cardiovascular disease event ( myocardial infarction , stroke , symptomatic peripheral artery disease , coronary bypass surgery , percutaneous coronary peripheral artery angioplasty ) past 6 month Pregnancy intention become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Insulin action</keyword>
	<keyword>Jet injector</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Insulin analog</keyword>
	<keyword>Insulin aspart</keyword>
</DOC>